EMA/108918/2023

European Medicines Agency decision

P/0139/2023

of 14 April 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2), (EMEA-003184-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0139/2023

of 14 April 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2), (EMEA-003184-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bavarian Nordic A/S on 7 April 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 February 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2), dispersion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2), dispersion for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to to Bavarian Nordic A/S, Philip Heymans Allee 3, 2900 – Hellerup, Denmark.

EMA/PDCO/902594/2022
Amsterdam, 24 February 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-003184-PIP01-22

Scope of the application

Active substance(s):

AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2)

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Dispersion for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Bavarian Nordic A/S

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bavarian Nordic A/S submitted for agreement to the European Medicines Agency on 7 April 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 May 2022.

Supplementary information was provided by the applicant on 21 November 2022. The request for a waiver was removed due to the addition of a primary vaccination series.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Prevention of COVID-19

2.1.1. Indication(s) targeted by the PIP

Prevention of COVID-19

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	**Study 1** Open-label, single-arm study to assess the immunogenicity and safety of AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2) in infants, toddlers, children and adolescents from 6 months of age to less than 18 years of age as a booster dose for the prevention of COVID-19. **Study 2** Open-label, single-arm study to assess the immunogenicity and safety of AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2) in immunocompromised infants, toddlers, children and adolescents from 6 months of age to less than 18 years of age as a booster dose for the prevention of COVID-19. **Study 3** Randomized, double blind, active controlled study of safety and immunogenicity and open label safety expansion of a primary series of AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2) for the prevention of Coronavirus disease 2019 (COVID-19) in children from birth to less than 5 years of age.

Modelling and simulation studies	Not applicable
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.